The listing gives the US Department of Defense and Veterans Affairs facilities access to Symvess for treating military personnel and other eligible patients, the company said.

Symvess received the US Food and Drug Administration's approval in December 2024 to treat extremity vascular trauma, Humacyte said.

http://www.mtnewswires.com
Copyright © 2025 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.